The document provides an overview of Thailand's medical device regulatory process and requirements. It discusses how medical devices are classified based on risk levels and the documentation required for registration. Registration requirements depend on the device's classification, with higher risk devices requiring more documentation. The process involves business registration, product registration or notification, and renewal every five years. It notes the increased costs and documentation under the new risk-based classification system compared to the past.
Thailand's medical devices sector is one of the most well-known and well-established sectors in ASEAN countries. To better illustrate, the trade value for this industry is 19.93 billion US dollars.
Submission requirements and Purpose, Details of Submission requirements and strategies, Submission timelines and cost, Differences between Japan and US submission processes
NOTE - This presentation was made as part of an assignment for a Course PME 542 (Regulation and Compliance in the Pharmaceutical Industry) at Stevens Institute of Technology, Hoboken, New Jersey
Prepared By - Ravi Goswami, Darold Hill, Shobha Dalal and Kuldeep Badoniya
This presentation is an overview of the Medical Device Regulatory Process for China. I used this to teach about SFDA Order No. 27, the amendments, Order No. 15 (Classification), Order No. 16 (Registration), YY, GB, YY/T, GB/T, YZB standards and the different registration forms to use for devices made in People\'s Republic of China, about imported medical devices, and about devices allowed from Taiwan, Hong Kong and Macau regions.
Thailand's medical devices sector is one of the most well-known and well-established sectors in ASEAN countries. To better illustrate, the trade value for this industry is 19.93 billion US dollars.
Submission requirements and Purpose, Details of Submission requirements and strategies, Submission timelines and cost, Differences between Japan and US submission processes
NOTE - This presentation was made as part of an assignment for a Course PME 542 (Regulation and Compliance in the Pharmaceutical Industry) at Stevens Institute of Technology, Hoboken, New Jersey
Prepared By - Ravi Goswami, Darold Hill, Shobha Dalal and Kuldeep Badoniya
This presentation is an overview of the Medical Device Regulatory Process for China. I used this to teach about SFDA Order No. 27, the amendments, Order No. 15 (Classification), Order No. 16 (Registration), YY, GB, YY/T, GB/T, YZB standards and the different registration forms to use for devices made in People\'s Republic of China, about imported medical devices, and about devices allowed from Taiwan, Hong Kong and Macau regions.
Medical Devices registration in Japan , quality system requirements and evaluation and investigation of medical devices in regulated countries ASEAN, China JAPAN and WHO regulations. quality and ethical considerations regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.
Premarket Notification The 510(k) ProcessMichael Swit
June 5, 2012 presentation to the Food & Drug Law Institute Introduction to Medical Device Law Conference, Palo Alto, CA, focusing on:
I.The Legal Framework For 510(k) Determinations
II.510(k) Preparation – From Planning to Content
A. Predicates: researching predicates, combination predicates, and pre-amendment predicates
B. Strategy: choosing the right claim and introducing new features
C. Assessing data requirements/pre-IDE meetings
III. Device Modifications - Choosing The Right Regulatory Mechanism
IV.The FDA Review
V.What To Do When Your Substantial Equivalence Argument Is Rejected
V. Special Topics: User Fees, Combination Products
VI. Lessons Learned: Seeing The 510(k) From The Reviewer’s Perspective
VII. Recent Trends, 510(k) Reform
VIII. Case Study
FDA Regulations and Medical Device Pathways to MarketMethodSense, Inc.
Bringing your medical device to market requires in-depth attention to its safety, reliability and compliance. In addition to designing a quality medical device, it’s critical that you anticipate and address the requirements that allow you to introduce it to the market successfully.
Life Science consulting firm, MethodSense, discusses important FDA regulations as they relate to bringing a medical device to market, including 21 CFR Part 821, 510(k) approval and 21 CFR Part 11.
How to Prepare for and Make the Most Out of your FDA Pre-Submission: Leverage...Greenlight Guru
The FDA Pre-Submission process is one the most effective tools out there to de-risk your 510(k) yet it is often both under-utilized and used improperly.
The Pre-Sub allows for device manufacture to discuss and get feedback directly from FDA on both their product development and regulatory strategy.
When used properly the Pre-Sub process can result in significant time savings to market - however when used improperly or ignored all together, this can easily result in unnecessary delays and wasted money.
This presentation covers:
- What is a Pre-Sub and why it is so important
- How to prepare and get the most out of your Pre-Sub
- The exact Pre-Sub timeline of events
- An example of the contents to include and how to format your Pre-Sub
- What you should do after your Pre-Sub
- A step-by-step case study example of the Pre-Sub process
Watch the presentation with commentary here: https://www.greenlight.guru/webinar/fda-pre-submission-process
Japan Medical Device Regulatory Approval ProcessKate Jablonski
Before deciding to sell your device in the Japanese market, it is important to understand how the regulations apply to your device, which steps to take, and what resources are required to complete the process. In this presentation, Ann Marie Boullie, Vice President of Business Development for EMERGO, outlines some of the most complex aspects of the Japanese registration process, including:
JMDN codes: device classification and predicates
Clinical data requirements and PMDA pre-submission meetings
Registration routes (Todokede, Ninsho, Shonin)
QMS (Ordinance 169) requirements
Role of the Marketing Authorization Holder (MAH)
Introduction
Definition
Classification
Regulatory registration procedure
Quality system requirements
Clinical evaluation
Investigation of medical devices
Summary
Medical devices are regulated by the National Medical Product Administration (NMPA), formerly the China Food and Drug Administration (CFDA)
Manufacturers must register their devices with the NMPA before selling or distributing in China.
The NMPA reviews all device applications and has strict requirements for submission documentation, testing, and clinical data.
Any instrument, apparatus, appliance, material, or other article whether used alone or in combination, including the software necessary for its proper application.
Diagnosis, prevention, monitoring, treatment or alleviation of disease
Diagnosis, monitoring, treatment, alleviation of compensation for an injury or handicap conditions
Investigation, replacement or modification for anatomy or a physiological process
Control of conception
The Chinese authorities (CFDA/NMPA) have their own quality management system requirements.
However, these “GMP requirements” are very similar to ISO 13485.
Therefore, manufacturers usually submit the ISO 13485 certificate.
However, the audit will review this certificate against the Chinese GMP requirements.
These audits are regularly carried out during the approval procedure and/or after a recall.
NMPA issued and implemented the "Guideline on Inspection of Quality Management System for Medical Device Registration" on October 10, 2022.
Product Life-cycle Process
The guideline specifies the basic requirements for registration inspection, self-inspection, commissioned inspection, and extended inspection, etc. Applicant needs to:
Ensure the design, development, production, and other process data to be true, accurate, complete, and traceable, and consistent with the registration application materials.
Carry out the registration QMS inspection in reference to the registration application materials, and focus on the design, development, procurement, production management, and quality control of the product.
For lower-risk medical devices (Class I and Class II), clinical evaluation may not always be required. However, higher-risk devices (Class III and implantable devices) generally require clinical evaluation.
The evaluation involves reviewing existing clinical data, scientific literature, and relevant clinical research to assess the safety and performance of the device.
All clinical trials for medical devices must follow China Good Clinical Practices
Clinical investigations are required if no equivalent devices can be found and safety and efficacy cannot be proven with other clinical and non-clinical data.
For certain medical devices, the NMPA may require clinical investigations, especially for novel devices or those with significant risk.
Clinical investigations involve conducting studies on human subjects to generate clinical data on the safety and effectiveness of the device.
To comprehend the regulatory requirements to import medical Medical devices and authorization procedures in regulated markets of the United States and Australia
Medical device management in china and latest regulatory updates_EdwinCIRS China
Currently, China is one of the world's most promising markets for medical devices, which on the back of its vast market size, offers huge potential to medical device companies. All medical devices marketed or sold for use in China must be registered with China Food and Drug Administration (CFDA).
A complete scenario of Medical Device Industry Of USA and India as well as of some major players. The presentation also highlights the Rules and regulations with respect to the devices and also SWOT analysis of emerging markets
Medical Devices registration in Japan , quality system requirements and evaluation and investigation of medical devices in regulated countries ASEAN, China JAPAN and WHO regulations. quality and ethical considerations regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.
Premarket Notification The 510(k) ProcessMichael Swit
June 5, 2012 presentation to the Food & Drug Law Institute Introduction to Medical Device Law Conference, Palo Alto, CA, focusing on:
I.The Legal Framework For 510(k) Determinations
II.510(k) Preparation – From Planning to Content
A. Predicates: researching predicates, combination predicates, and pre-amendment predicates
B. Strategy: choosing the right claim and introducing new features
C. Assessing data requirements/pre-IDE meetings
III. Device Modifications - Choosing The Right Regulatory Mechanism
IV.The FDA Review
V.What To Do When Your Substantial Equivalence Argument Is Rejected
V. Special Topics: User Fees, Combination Products
VI. Lessons Learned: Seeing The 510(k) From The Reviewer’s Perspective
VII. Recent Trends, 510(k) Reform
VIII. Case Study
FDA Regulations and Medical Device Pathways to MarketMethodSense, Inc.
Bringing your medical device to market requires in-depth attention to its safety, reliability and compliance. In addition to designing a quality medical device, it’s critical that you anticipate and address the requirements that allow you to introduce it to the market successfully.
Life Science consulting firm, MethodSense, discusses important FDA regulations as they relate to bringing a medical device to market, including 21 CFR Part 821, 510(k) approval and 21 CFR Part 11.
How to Prepare for and Make the Most Out of your FDA Pre-Submission: Leverage...Greenlight Guru
The FDA Pre-Submission process is one the most effective tools out there to de-risk your 510(k) yet it is often both under-utilized and used improperly.
The Pre-Sub allows for device manufacture to discuss and get feedback directly from FDA on both their product development and regulatory strategy.
When used properly the Pre-Sub process can result in significant time savings to market - however when used improperly or ignored all together, this can easily result in unnecessary delays and wasted money.
This presentation covers:
- What is a Pre-Sub and why it is so important
- How to prepare and get the most out of your Pre-Sub
- The exact Pre-Sub timeline of events
- An example of the contents to include and how to format your Pre-Sub
- What you should do after your Pre-Sub
- A step-by-step case study example of the Pre-Sub process
Watch the presentation with commentary here: https://www.greenlight.guru/webinar/fda-pre-submission-process
Japan Medical Device Regulatory Approval ProcessKate Jablonski
Before deciding to sell your device in the Japanese market, it is important to understand how the regulations apply to your device, which steps to take, and what resources are required to complete the process. In this presentation, Ann Marie Boullie, Vice President of Business Development for EMERGO, outlines some of the most complex aspects of the Japanese registration process, including:
JMDN codes: device classification and predicates
Clinical data requirements and PMDA pre-submission meetings
Registration routes (Todokede, Ninsho, Shonin)
QMS (Ordinance 169) requirements
Role of the Marketing Authorization Holder (MAH)
Introduction
Definition
Classification
Regulatory registration procedure
Quality system requirements
Clinical evaluation
Investigation of medical devices
Summary
Medical devices are regulated by the National Medical Product Administration (NMPA), formerly the China Food and Drug Administration (CFDA)
Manufacturers must register their devices with the NMPA before selling or distributing in China.
The NMPA reviews all device applications and has strict requirements for submission documentation, testing, and clinical data.
Any instrument, apparatus, appliance, material, or other article whether used alone or in combination, including the software necessary for its proper application.
Diagnosis, prevention, monitoring, treatment or alleviation of disease
Diagnosis, monitoring, treatment, alleviation of compensation for an injury or handicap conditions
Investigation, replacement or modification for anatomy or a physiological process
Control of conception
The Chinese authorities (CFDA/NMPA) have their own quality management system requirements.
However, these “GMP requirements” are very similar to ISO 13485.
Therefore, manufacturers usually submit the ISO 13485 certificate.
However, the audit will review this certificate against the Chinese GMP requirements.
These audits are regularly carried out during the approval procedure and/or after a recall.
NMPA issued and implemented the "Guideline on Inspection of Quality Management System for Medical Device Registration" on October 10, 2022.
Product Life-cycle Process
The guideline specifies the basic requirements for registration inspection, self-inspection, commissioned inspection, and extended inspection, etc. Applicant needs to:
Ensure the design, development, production, and other process data to be true, accurate, complete, and traceable, and consistent with the registration application materials.
Carry out the registration QMS inspection in reference to the registration application materials, and focus on the design, development, procurement, production management, and quality control of the product.
For lower-risk medical devices (Class I and Class II), clinical evaluation may not always be required. However, higher-risk devices (Class III and implantable devices) generally require clinical evaluation.
The evaluation involves reviewing existing clinical data, scientific literature, and relevant clinical research to assess the safety and performance of the device.
All clinical trials for medical devices must follow China Good Clinical Practices
Clinical investigations are required if no equivalent devices can be found and safety and efficacy cannot be proven with other clinical and non-clinical data.
For certain medical devices, the NMPA may require clinical investigations, especially for novel devices or those with significant risk.
Clinical investigations involve conducting studies on human subjects to generate clinical data on the safety and effectiveness of the device.
To comprehend the regulatory requirements to import medical Medical devices and authorization procedures in regulated markets of the United States and Australia
Medical device management in china and latest regulatory updates_EdwinCIRS China
Currently, China is one of the world's most promising markets for medical devices, which on the back of its vast market size, offers huge potential to medical device companies. All medical devices marketed or sold for use in China must be registered with China Food and Drug Administration (CFDA).
A complete scenario of Medical Device Industry Of USA and India as well as of some major players. The presentation also highlights the Rules and regulations with respect to the devices and also SWOT analysis of emerging markets
Device registration and listing of medical devices on the US marketttopstart B.V.
We provide an overview of the regulations and legislations with regard to commercialisation of medical devices in the US. The product category of medical devices ranges from class I devices up to class III devices. In the US, market approval is granted by the FDA (Food and Drug Administration) upon assessment of quality, safety and effectiveness.
The information provided here informs start-ups, spin-offs and biotech companies about the differences in regulatory procedures for specific classes of medical devices. By summarising the procedures for each class of medical device, we, ttopstart, aim to offer a guide through this dense regulative and legislative landscape. These insights can be used to design the optimal market introduction strategy for your medical device.
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
Full description of the regulatory process for the medical devices registration in South Korea. It contains information about: classification, substantial equivalence, product license, testing, Korean Good Manufacturing Practice (KGMP)...
Find more on: http://kobridgeconsulting.com/?p=767
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Medical devices update on the thai fda regulatory process and requirements
1. MEDICAL DEVICES:
Update on the Thai FDA Regulatory
Process and Requirements
Atthachai Homhuan, PhD
Director Regulatory Affairs
2. Our legal services cover the full range of issues
faced by businesses in Southeast Asia
2
Antitrust and competition
Banking and finance
Capital markets
Commercial Transactions and M&A
Corporate Services
Employment
Energy and infrastructure
Insurance
Property
Tax
Technology, media, and telecoms
Transportation and logistics
Anticounterfeiting
Copyrights
Geographical indications
Government relations
IP commercialization
IP enforcement
IP litigation
Patents, petty patents, and designs
Regulatory affairs
Strategic filing advice
Trademarks
Trade secrets
Bankruptcy and reorganizations
Constructions disputes
Contract disputes
Customs valuation
Director’s liability
Insurance disputes
International trade disputes
Labor litigation
Product liability
Shareholder disputes
Shipping and maritime disputes
Tax litigation
White-collar crime
Wrongful act
Corporate and
Commercial
Dispute Resolution
and Litigation
Intellectual
Property
3. 3
Who is Tilleke & Gibbins?
Our regional presence
helps clients do business
across Southeast Asia
Vientiane Jakarta
Bangkok
Yangon Ho Chi Minh City
Hanoi
Phnom Penh
4. Outline of Presentation
4
Overview of the Medical Device Regulations in Thailand
Important regulatory requirements of medical devices/digital solutions that
the industry should know
Process of submission (timeframe, key costs, documents)
Tips for successful registration of a medical device in Thailand
5. Registration of a medical device is similar to
“attempting an uphill task”
5
“Medical Device” means:
A device, an appliance, a mechanical tool, an object inserted into the body, a solution used
for performing a test inside or outside a laboratory, a product, software or any other object
specifically intended by the manufacturer or owner to be used, for any one or more of the
following purposes, on human-beings or animals, whether independently from, in
conjunction with or as an accessory of any other article:
Medical Device Act No. 1 (2008)
and No. 2 (2019)
Key to success: Industry must
understand the regulatory landscape
6. Definition of medical device (continued)
6
1. (a) conducting diagnosis, prevention, monitoring, alleviation or treatment of a disease;
(b) conducting diagnosis, monitoring, treatment, alleviation or treatment of an injury;
. . .
(g) providing information from the examination of body specimens for a medical purpose or for a diagnosis;
(h) performing disinfection or sterilization of medical devices;
2. Supplementary equipment for use in conjunction with a medical device under (1);
3. A device, appliance, mechanical tool, product or any other object prescribed in the Notification of the Minister as a
medical device;
provided that the achievement of the purposes of the articles mentioned under (1) occurring in the human or
animal body must not principally result from:
a pharmacological or
an immunological process or
a metabolic reaction.
7. 7
Thailand: Medical Device VS Drug Product
Simethicone
anti-gas (anti-flatulence)
medication, acting via the change of
the surface tension of gas bubbles
Eyewash solution
Although these products meet the
medical device definition and they are
not acting via:
a pharmacological or
an immunological process or
a metabolic reaction
In Thailand, they are drug products
according to the Drug Act.
Recent Changes in Product Classifications
from drug product to medical device
such as Hyaluronic acid dermal fillers;
contact lens solutions, etc.
Saline Solution
8. For consumer safety,
the product is about
to become a
Medical Device
as announced
by the Minister
Because of the COVID-19
outbreak, the reclassification
of Alcohol-Based Hand
Sanitizer as a medical device
is cancelled.
Alcohol-Based Hand
Sanitizer will continue to
be classified as a
Cosmetic
Alcohol Concentration (Ethanol, Isopropanol, n-Proponol)
of lower than 70 %v/v is now banned in Thailand.
Lotion, Solution, Cream, Gel, Foam, Spray
2018-2019
8
Alcohol-Based Hand Sanitizer
Originally, a product
is either a
Drug or Cosmetic
9. Establishment of Business Place Registration
1
Importer
Domestic Manufacturer
Product Registration/Notification
2
9
FDA Regulatory Landscape and Requirements
Medical Device
• Government fee THB 16,100
• Approval Timeframe 30 business days
• Renewable (every 5 years)
10. Establishment of Business Place Registration
as an Importer
10
Before importation of a medical device for sale in Thailand, the importer must obtain a business place registration as a medical device
importer.
The importer must:
Be the owner of the business and have sufficient assets and structure to be able to establish and operate the business;
Appoint a business operator who is at least 20 years of age and a resident of Thailand;
Not have been convicted of an offense against certain laws (for example, laws concerning narcotics and psychotropic
substances);
Have the premises to import or sell medical devices and equipment for use in the storage of devices and the control or
maintenance of the quality and quantity as prescribed in ministerial regulations; and
Use a trade name for the business that is not a repetition of, or similar to, the trade name used by another active licensee or a
licensee whose license has been suspended or revoked for less than a full year.
After the business place registration license has been obtained, the medical devices must be registered with the Thai Food and Drug
Administration (‘FDA’) prior to being imported/domestically manufactured in Thailand.
The license is valid for 5 years and it is renewable.
11. Medical Device Classification
Medical devices are classified into three (3) categories, i.e.
Listed (or previously called General) medical devices (low risk, risk class 1);
Detailed Notification medical device (moderate, moderate to high risk or risk class 2, 3); and
Licensed medical device (high risk, or risk class 4).
Previously, classifications of each medical device were determined by the Thai FDA, according to
Thailand’s specific circumstances, wherein the classifications of particular medical devices would be
announced in Notifications of the Ministry of Public Health.
Medical devices that pose a high risk or impact the public in the view of the Thai FDA, i.e. HIV test
kits, hyaluronic acid dermal fillers, condoms, prosthetic silicone breast implants, and contact lenses,
etc., were prescribed in the Ministerial Notifications as either Detailed Notification Medical Devices or
Licensed Medical Devices.
Other medical devices that were not prescribed in the Ministerial Notifications would be classified as
General Medical Devices (or Listed Medical Devices). According to the former classification system,
most medical devices in Thailand were classified as Listed Medical Devices.
11
12. Product Registration
2
The registration requirements depend on the category of the medical device, which is
associated with the risk of the medical device.
A Medical Device is classified into three categories according to the Medical Device Act (2008), as amended.
Class 1 Low-Risk
Class 2 Low- to Moderate-Risk
Class 3 Moderate- to High-Risk
Class 4 High-Risk
Listed (General) Medical Device
Detailed Notification
Medical Device
Licensed Medical Device
In the past, the Thai FDA announced particular
devices categorized into the designated
categories above.
Currently, the Medical Device industry must determine the
risk of its medical device independently by referring to the
risk classification system of the ASEAN Medical Device
Directive. Medical Devices are classified into four classes,
depending on the level of risk to individuals and the general
public. For example, Class 4 = Licensed Medical Device.
13. 13
“New Importer” (first time in Thailand)
*CSDT = Common Submission Dossier Template
Burdens for a Medical Device importer/domestic manufacturer
For example, in the past, a Medical Device with a Class 3 risk in another country was designated a General
Medical Device in Thailand. Its registration timeline was about 15 days and required only few documents.
But today, because of the new registration scheme, it is classified as a Detailed Notification Medical Device.
Submission of Renewal Application every 5 years
Submission of
Registration Application
(15 Feb 2021 – 15 Feb 2024)
Licensed Medical Device (risk 4)
Detailed Notification Medical Device (risk 2-3)
Listed Medical Device (risk class 1)
Abbreviated CSDT*
or Full CSDT
for Risk 2-4
Obtain Registration
Approval with
5 years’ validity
Renewal
Submission of Full CSDT* +
Obtain the Renewal Approval
14. 15 FEB 2021
Implementation of Risk
Classification System
15 FEB 2024
Full CSDT is Required
3 Years Relaxation
Period
Abbreviated Version of CSDT
• Applicable for Licensed Medical Device and Detailed Notification Medical Device
14
“New Importer” (first time in Thailand)
15. Documentation Required for a Listed Medical Device (Class 1)
List of Required Documentation
Normal
Registration
Scheme
Abbreviated CSDT
(Applicable for old
importer only)
Device Description / Product Specification
Device Labeling/Package Insert
Manufacturer Information
Declaration of Conformity (DOC)
Letter of Authorization for Authorized Representatives
Commercial Marketing History (if applicable)
Other Documents, such as descriptions of materials, sterility test
reports (if applicable), calibration test reports (if applicable).
15
16. Documentation Required for a Detailed Notification
Medical Device (Class 2 or Class 3)
List of Required Documentation
Normal
Registration
Scheme (Full CSDT)
Abbreviated
CSDT
Executive Summary
Essential Principles of Safety and Performance of Medical Devices and Method Used to Demonstrate Conformity
Device Description
Summary Of Design Verification and Validation Documents
Device Labeling/Package Insert
Risk Analysis
Manufacturer Information
Disposition And Waste Management
Quality Management System Certificate (i.e. ISO 13485, ISO 9001, GMP, etc.)
Declaration of Conformity (DOC)
Letter of Authorization for Authorized Representatives
Evidence of Registration Approval obtained in other countries
Commercial Marketing History
Declaration Forms related to intended use, label, packing, etc., issued by manufacturer or product owner
Declaration Forms related to safety of medical device, issued by manufacturer or product owner
16
17. Documentation Required for a Licensed Medical Device (Class 4)
List of Required Documentation
Normal
Registration
Scheme (Full CSDT)
Abbreviated
CSDT
Executive Summary
Essential Principles of Safety and Performance of Medical Devices and Method Used to Demonstrate Conformity
Device Description
Summary Of Design Verification and Validation Documents
Device Labeling/Package Insert
Risk Analysis
Manufacturer Information
Disposition And Waste Management
Quality Management System Certificate (i.e. ISO 13485, ISO 9001, GMP, etc.)
Declaration of Conformity (DOC)
Letter of Authorization for Authorized Representatives
Evidence of Registration Approval obtained in other countries
Commercial Marketing History
Declaration Forms related to intended use, label, packing, etc., issued by manufacturer or product owner
Declaration Forms related to safety of medical device, issued by manufacturer or product owner
17
18. Detailed Notification
Medical Device
Moderate- to High-Risk (Classes 2-3)
Time Frame: 160 business days
Government Fee: THB 49,000 (Class 2)
THB 74,000 (Class 3)
Listing (General)
Medical Device
Low-Risk (Class 1)
Time Frame: 30 business days
Government Fee: THB 3,000
Licensed
Medical Device
High-Risk (Class 4)
Time Frame: 200 business days
Government Fee: THB 109,000
Previously, almost all Medical Devices in Thailand were classified as Listing Medical Devices. Currently, Medical Device
importers or domestic manufacturers must allocate sufficient budget funds for the registration of their Medical
Devices in Thailand, as the government fees have significantly increased.
Registration Timeline and Government Fees
18
19. 30 business days
The Manufacturer or Importer must
1. Prepare its premises,
equipment, storage
room, as prescribed
by law.
4. Advertisement of a
medical device to the
public must receive prior
approval from the FDA.
3. Post-marketing
Surveillance, product
recall and field safety
corrective action.
2. Submission of dossier with
the FDA. Some medical
devices (e.g., IVD) require
test reports.
19
Tips for the Medical Device industry
20. Digital health in Thailand
20
Thailand is currently ranked the third most rapidly expanding ageing population in the world
Talented and skillful physicians/healthcare professionals and world class hospitals
COVID-19 pandemic
These factors create ideal conditions for digital health solutions in Thailand. There are several Government
programs now available to digital health solution providers.
The idea of “digital health” or “telemedicine” generally falls within the area of Medical Device regulation as
well.
Software and device accessories used for the diagnosis, monitoring, prevention, or treatment of illnesses would
fall under the Medical Device classifications (such as the mobile medical apps, wearable technologies and
software).
Also relevant ate the Personal Data Protection Act (PDPA) 2019 and the National Cyber Security Act 2019 (these
laws involve personal data protection, consent, data control measures, transfer of data, privacy issues, etc.)